CTLA4 and colon adenocarcinoma: However, the success rate of immune checkpoint inhibition is not ideal, and there are still abundant cancers refractory to CTLA-4 and PD-1 blockade, like colon adenocarcinoma (COAD) (Das et al., 2017; O'Connell et al., 2021).